Enliven Therapeutics (ELVN) Net Income towards Common Stockholders (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 12.11% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$117.1 million (down 5.73% YoY), and the FY2025 full-year result was -$147.5 million, up 15.24% from the prior year.
• Net Income towards Common Stockholders advanced to -$27.9 million in Q1 2026, from -$34.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$8.9 million in Q1 2022 to a low of -$58.4 million in Q4 2023.
• A 5-year average of -$25.5 million and a median of -$26.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 120.32% in 2023 and surged 53.89% in 2024, its largest moves.
• Tracing ELVN's Net Income towards Common Stockholders over 5 years: stood at -$29.7 million in 2022, then sank by 96.61% to -$58.4 million in 2023, then surged by 53.89% to -$26.9 million in 2024, then declined by 27.7% to -$34.4 million in 2025, then climbed by 18.82% to -$27.9 million in 2026.
• Business Quant data shows ELVN's Net Income towards Common Stockholders at -$27.9 million in Q1 2026, -$34.4 million in Q4 2025, and -$25.6 million in Q3 2025.